DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: Moreover, regarding the available mutation-specific therapies for Dystrophinopathy, the precise characterization of the DMD mutation allowed us to determine that 20 patients were candidates for exon skipping of exon 51, 21 for exon 53 and 12 for exon 45, while another 70 were eligible for premature stop codon read-through therapy (Table 1).